We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #3 (Hold) but that could change following its first-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson’s adjusted earnings of $2.33 per share beat the Zacks Consensus Estimate by 22 cents and increased from $1.96 posted in the year-ago quarter on a currency-neutral basis.
Becton, Dickinson and Company Price and EPS Surprise
Revenues: Adjusted revenues amounted to $2.92 billion, down 2.1% from the year-ago quarter on a comparable currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $2.85 billion.
Key Stats: BD Medical generated revenues of $1.96 billion, down 4.4% on a year-over-year basis. BD Lifesciences generated revenues of $958 million, up 2.7% from the year-ago quarter. On a comparable basis, adjusted U.S. revenues increased 5.5%. International revenues increased 6.8% on a currency-neutral basis in the reported quarter.
Major Factors: BD Medical’s year over year growth reflects strong performance in the Pharmaceutical Systems and Medication Management Solutions units. Revenue growth in the BD Lifesciences segment reflects strong performance in the Diagnostic Systems and Preanalytical Systems units.
Check back later for our full write up on this Becton, Dickinson and Company earnings report!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Becton, Dickinson (BDX) Beats Q1 Earnings & Revenues
Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #3 (Hold) but that could change following its first-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson’s adjusted earnings of $2.33 per share beat the Zacks Consensus Estimate by 22 cents and increased from $1.96 posted in the year-ago quarter on a currency-neutral basis.
Becton, Dickinson and Company Price and EPS Surprise
Becton, Dickinson and Company Price and EPS Surprise | Becton, Dickinson and Company Quote
Revenues: Adjusted revenues amounted to $2.92 billion, down 2.1% from the year-ago quarter on a comparable currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $2.85 billion.
Key Stats: BD Medical generated revenues of $1.96 billion, down 4.4% on a year-over-year basis. BD Lifesciences generated revenues of $958 million, up 2.7% from the year-ago quarter. On a comparable basis, adjusted U.S. revenues increased 5.5%. International revenues increased 6.8% on a currency-neutral basis in the reported quarter.
Major Factors: BD Medical’s year over year growth reflects strong performance in the Pharmaceutical Systems and Medication Management Solutions units. Revenue growth in the BD Lifesciences segment reflects strong performance in the Diagnostic Systems and Preanalytical Systems units.
Check back later for our full write up on this Becton, Dickinson and Company earnings report!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>